Multiple approaches to repurposing drugs for neuroblastoma.

ABSTRACT: Neuroblastoma (NB) is the second leading extracranial solid tumor of early childhood with about two-thirds of cases presenting before the age of 5, and accounts for roughly 15 percent of all pediatric cancer fatalities in the United States. Treatments against NB are lacking, resulting in a low survival rate in high-risk patients. A repurposing approach using already approved or clinical stage compounds can be used for diseases for which the patient population is small, and the commercial market limited. We have used Bayesian machine learning, in vitro cell assays, and combination analysis to identify molecules with potential use for NB. We demonstrated that pyronaridine (SH-SY5Y IC₅₀ 1.70 µM, SK-N-AS IC₅₀ 3.45 µM), BAY 11-7082 (SH-SY5Y IC₅₀ 0.85 µM, SK-N-AS

SUBMITTER: Rank L 

PROVIDER: S-EPMC9870653 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature